메뉴 건너뛰기




Volumn 22, Issue 7, 2006, Pages 1403-1413

Randomized, open-label comparison of epoetin alfa extended dosing (80 000 U Q2W) vs weekly dosing (40 000 U QW) in patients with chemotherapy-induced anemia

Author keywords

Anemia; Cancer; Epoetin alfa; Extended dosing; Randomized trial; Transfusions

Indexed keywords

ANTINEOPLASTIC AGENT; FERROUS SULFATE; HEMOGLOBIN; PLATINUM DERIVATIVE; RECOMBINANT ERYTHROPOIETIN;

EID: 33746105013     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X115559     Document Type: Conference Paper
Times cited : (21)

References (20)
  • 1
    • 0033530262 scopus 로고    scopus 로고
    • Chemotherapy-induced anemia in adults: Incidence and treatment
    • Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999;91:1616-34
    • (1999) J Natl Cancer Inst , vol.91 , pp. 1616-1634
    • Groopman, J.E.1    Itri, L.M.2
  • 2
    • 21744439534 scopus 로고    scopus 로고
    • The anaemia of cancer: Death by a thousand cuts
    • Spivak JL. The anaemia of cancer: death by a thousand cuts. Nat Rev Cancer 2005;5:543-55
    • (2005) Nat Rev Cancer , vol.5 , pp. 543-555
    • Spivak, J.L.1
  • 3
    • 0035367087 scopus 로고    scopus 로고
    • Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving non-platinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial
    • Littlewood TJ, Bajetta E, Nortier JWR, et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving non-platinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001;19:2865-74
    • (2001) J Clin Oncol , vol.19 , pp. 2865-2874
    • Littlewood, T.J.1    Bajetta, E.2    Nortier, J.W.R.3
  • 4
    • 4344627592 scopus 로고    scopus 로고
    • Treatment of cancer-related anemia with epoetin alfa: A review
    • Ferrario E, Ferrari L, Bidoli P, et al. Treatment of cancer-related anemia with epoetin alfa: a review. Cancer Treat Rev 2004;30:563-75
    • (2004) Cancer Treat Rev , vol.30 , pp. 563-575
    • Ferrario, E.1    Ferrari, L.2    Bidoli, P.3
  • 5
    • 0031785039 scopus 로고    scopus 로고
    • Impact of epoetin alfa in chemotherapy-associated anemia
    • Jilani SM, Glapsy JA. Impact of epoetin alfa in chemotherapy-associated anemia. Semin Oncol 1998;25:571-6
    • (1998) Semin Oncol , vol.25 , pp. 571-576
    • Jilani, S.M.1    Glapsy, J.A.2
  • 6
    • 0036787775 scopus 로고    scopus 로고
    • Use of epoetin alfa in patients with cancer: Evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology
    • Rizzo JD, Lichtin AE, Woolf SH, et al. Use of epoetin alfa in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 2002;20:4083-107
    • (2002) J Clin Oncol , vol.20 , pp. 4083-4107
    • Rizzo, J.D.1    Lichtin, A.E.2    Woolf, S.H.3
  • 7
    • 0035366382 scopus 로고    scopus 로고
    • Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: Improvements in hemoglobin and quality of life are similar to three-times-weekly dosing
    • Gabrilove JL, Cleeland CS, Livingston RB, et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001;19:2875-82
    • (2001) J Clin Oncol , vol.19 , pp. 2875-2882
    • Gabrilove, J.L.1    Cleeland, C.S.2    Livingston, R.B.3
  • 8
    • 26444555509 scopus 로고    scopus 로고
    • Randomized comparison of epoetin alfa (40,000 U weekly) and darbepoetin alfa (200 μg every 2 weeks) in anemic patients with cancer receiving chemotherapy
    • Waltzman R, Croot C, Justice GR, et al. Randomized comparison of epoetin alfa (40,000 U weekly) and darbepoetin alfa (200 μg every 2 weeks) in anemic patients with cancer receiving chemotherapy. Oncologist 2005;10:642-50
    • (2005) Oncologist , vol.10 , pp. 642-650
    • Waltzman, R.1    Croot, C.2    Justice, G.R.3
  • 9
    • 21044442522 scopus 로고    scopus 로고
    • Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy
    • Witzig TE, Silberstein PT, Loprinzi CL, et al. Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol 2005;23:2606-17
    • (2005) J Clin Oncol , vol.23 , pp. 2606-2617
    • Witzig, T.E.1    Silberstein, P.T.2    Loprinzi, C.L.3
  • 10
    • 1642498304 scopus 로고    scopus 로고
    • Epoetin alfa 60,000 U once weekly followed by 120,000 U every 3 weeks increases and maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy
    • Patton J, Kuzur M, Liggett W, et al. Epoetin alfa 60,000 U once weekly followed by 120,000 U every 3 weeks increases and maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy. Oncologist 2004;9:90-6
    • (2004) Oncologist , vol.9 , pp. 90-96
    • Patton, J.1    Kuzur, M.2    Liggett, W.3
  • 11
    • 33644977733 scopus 로고    scopus 로고
    • Phase III study of two different dosing schedules of erythropoietin in anemic patients with cancer
    • Steensma DP, Molina R, Sloan JA, et al. Phase III study of two different dosing schedules of erythropoietin in anemic patients with cancer. J Clin Oncol 2006;24:1079-89
    • (2006) J Clin Oncol , vol.24 , pp. 1079-1089
    • Steensma, D.P.1    Molina, R.2    Sloan, J.A.3
  • 12
    • 26444599396 scopus 로고    scopus 로고
    • Raritan, NJ: Ortho Biotech Products, L.P.
    • PROCRIT® Package Insert. Raritan, NJ: Ortho Biotech Products, L.P.; 2005
    • (2005) PROCRIT® Package Insert
  • 13
    • 0042889128 scopus 로고    scopus 로고
    • Once-weekly dosing of epoetin-α increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy
    • Shasha D, George MJ, Harrison LB. Once-weekly dosing of epoetin-α increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy. Cancer 2003;98:1072-9
    • (2003) Cancer , vol.98 , pp. 1072-1079
    • Shasha, D.1    George, M.J.2    Harrison, L.B.3
  • 14
    • 25444497001 scopus 로고    scopus 로고
    • Retrospective observational study of patients with chemotherapy-related anemia receiving erythropoietic agents
    • Mark TL, McKenzie RS, Fastenau J, Piech CT. Retrospective observational study of patients with chemotherapy-related anemia receiving erythropoietic agents. Curr Med Res Opin 2005;21:1347-54
    • (2005) Curr Med Res Opin , vol.21 , pp. 1347-1354
    • Mark, T.L.1    McKenzie, R.S.2    Fastenau, J.3    Piech, C.T.4
  • 15
    • 17044394034 scopus 로고    scopus 로고
    • Evolving treatment approaches to early breast cancer
    • Campon SM. Evolving treatment approaches to early breast cancer. Breast Cancer Res Treat 2005;89(Suppl 1):S1-7
    • (2005) Breast Cancer Res Treat , vol.89 , Issue.SUPPL. 1
    • Campon, S.M.1
  • 16
    • 0036957334 scopus 로고    scopus 로고
    • Intensive sequential dose dense chemotherapy with stem cell support as first-line treatment in advanced ovarian carcinoma: A phase II study
    • Viret F, Bertucci F, Genre D, et al. Intensive sequential dose dense chemotherapy with stem cell support as first-line treatment in advanced ovarian carcinoma: a phase II study. Bone Marrow Transplant 2002;30:879-84
    • (2002) Bone Marrow Transplant , vol.30 , pp. 879-884
    • Viret, F.1    Bertucci, F.2    Genre, D.3
  • 17
    • 14644406208 scopus 로고    scopus 로고
    • Evaluation of anemia, neutropenia, and skin toxicities in standard or dose-dense doxorubicin/cyclophosphamide (AC)-paclitaxel or docetaxel adjuvant chemotherapy in breast cancer
    • Schwartz J, Domcheck SM, Hwang WT, Fox K. Evaluation of anemia, neutropenia, and skin toxicities in standard or dose-dense doxorubicin/ cyclophosphamide (AC)-paclitaxel or docetaxel adjuvant chemotherapy in breast cancer. Ann Oncol 2005;16:247-52
    • (2005) Ann Oncol , vol.16 , pp. 247-252
    • Schwartz, J.1    Domcheck, S.M.2    Hwang, W.T.3    Fox, K.4
  • 18
    • 28844440074 scopus 로고    scopus 로고
    • Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every 2 week adjuvant breast cancer chemotherapy
    • Burstein HJ, Parker LM, Keshaviah A, et al. Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every 2 week adjuvant breast cancer chemotherapy. J Clin Oncol 2005;23:8340-7
    • (2005) J Clin Oncol , vol.23 , pp. 8340-8347
    • Burstein, H.J.1    Parker, L.M.2    Keshaviah, A.3
  • 19
    • 33644818721 scopus 로고    scopus 로고
    • Benefits associated with an early hemoglobin response to epoetin alfa therapy in the treatment of chemotherapy-related anemia
    • Campos SM, Duh MS, Lefebvre P, Rosberg J. Benefits associated with an early hemoglobin response to epoetin alfa therapy in the treatment of chemotherapy-related anemia. J Natl Compr Cane Netw 2005;3:807-16
    • (2005) J Natl Compr Cane Netw , vol.3 , pp. 807-816
    • Campos, S.M.1    Duh, M.S.2    Lefebvre, P.3    Rosberg, J.4
  • 20
    • 27144435165 scopus 로고    scopus 로고
    • Early hemoglobin response and alternative metrics of efficacy with erythropoietic agents for chemotherapy-related anemia
    • Reed SD, Radheva JI, Daniel DB et al. Early hemoglobin response and alternative metrics of efficacy with erythropoietic agents for chemotherapy-related anemia. Curr Med Res Opin 2005;21:1527-33
    • (2005) Curr Med Res Opin , vol.21 , pp. 1527-1533
    • Reed, S.D.1    Radheva, J.I.2    Daniel, D.B.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.